MIRLET7BHG Polymorphisms Associated with Asbestos-related Lung Cancer
the Cancer Therapy Advisor take:
The interaction observed between single nucleotide polymorphisms (SNPs) and asbestos exposure correlated to increased lung cancer risk among MIRLET7BHG carriers, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
The study included 833 Caucasian cases and 739 Caucasian control participants. The authors identified SNPs with gene-asbestos interaction effects using a genome-wide association study (GWAS).
In groups with GWAS and asbestos exposure data (1,548 cases and 1,527 controls), in silico replication was conducted, followed by de novo genotyping to replicate the results from step one (1,539 cases and 1,761 controls).
Results showed a significant increase in lung cancer risk in participants who were variant allele(s) carriers of MIRLET7BHG (MIRLET7B host gene at 22q13.31) polymorphisms rs13053856, rs11090910, rs11703832, and rs12170325 [P<5×10-7 by likelihood ratio test; df=1].
The authors observed that among the participants who were variant allele(s) carriers, each unit increase in the natural log-transformed asbestos exposure score was associated with age-, sex-, smoking status- and center-adjusted ORs of 1.34(95% CI: 1.18, 1.51), 1.24(95% CI: 1.14, 1.35), 1.28(95% CI: 1.17, 1.40), and 1.26(95% CI: 1.15, 1.38), respectively for lung cancer risk.
Interaction between SNPs and asbestos exposure correlated to increased lung cancer risk in MIRLET7BHG carriers
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- First-Line Alectinib Effective in Asian Patients With ALK-Positive Advanced NSCLC
- Pembrolizumab Alone or With Chemotherapy Prolongs OS in Recurrent/Metastatic HNSCC
- Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma
- Assays May Help Researchers Discover Factors Underlying Immunotherapy Response
- Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer